

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior listings of claims in the application.

Claims 1-65 (Cancelled).

66. (Currently amended) An isolated antibody that specifically binds to a human interleukin-11 receptor (IL-11R) protein or a fragment thereof, wherein the human IL-11R protein or fragment thereof consists of an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:2;
- (b) the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 422;
- (c) the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 365;
- (d) the amino acid sequence of SEQ ID NO:2 from amino acids 391 to 422;
- (e) the amino acid sequence of SEQ ID NO:2 from amino acids 112 to 422;
- (f) the amino acid sequence of SEQ ID NO:2 from amino acids 112 to 365;
- (g) the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 359;
- (h) the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 345; and
- (i) the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 324.

67. (Previously presented) The antibody of claim 66, wherein said antibody is a neutralizing antibody.

68. (Previously presented) The antibody of claim 66, wherein said antibody blocks binding of IL-11 to a human IL-11 receptor.

69. (Previously presented) The antibody of claim 66, wherein said antibody is a polyclonal antibody.

70. (Previously presented) The antibody of claim 66, wherein said antibody is a monoclonal antibody.

71. (Previously presented) A pharmaceutical composition comprising the antibody of claim 66 and a pharmaceutically acceptable carrier.

72. (Currently amended) An isolated antibody that specifically binds to a human interleukin-11 receptor (IL-11R) ~~or a fragment thereof consisting of the amino acid sequence of SEQ ID NO:2 or consisting of the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 422.~~

Claim 73 (Canceled).

74 (Previously presented) The isolated antibody of claim 72, wherein said antibody is a neutralizing antibody.

75. (Previously presented) The antibody of claim 72, wherein said antibody blocks binding of IL-11 to a human IL-11 receptor.

76. (Previously presented) The antibody of claim 72, wherein said antibody is a polyclonal antibody.

77. (Previously presented) The antibody of claim 72, wherein said antibody is a monoclonal antibody.

78. (Previously presented) A pharmaceutical composition comprising the antibody of claim 72 and a pharmaceutically acceptable carrier.

Claims 79-89 (cancelled).